# US 6,727,244 B2 · Mammalian metabolites of a tachykinin receptor antagonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,244 B2
- Document ID: US6727244B2
- Status: Granted
- Kind: B2
- Application number: 10/415,205
- Filed: 2003-04-24
- Published: 2004-02-05
- Granted: 2004-04-27
- Earliest claimed: 2000-10-26
- Assignees: Merck & Co., Inc.
- Inventors: Su-er Wu Huskey; Shuet-Hing Lee Chiu
- Web page: https://patentgrep.com/patent/US6727244B2

## CPC

- C07D 265/33: Two oxygen atoms, in positions 3 and 5
- A61K 31/09: having two or more such linkages
- A61K 31/121: acyclic
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- C07C 43/315: containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
- C07C 45/28: of CHx-moieties
- C07C 45/64: by introduction of functional groups containing oxygen only in singly bound form
- C07C 45/71: being hydroxy groups
- C07C 49/255: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07C 49/84: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07C 59/88: containing halogen
- C07C 59/90: containing singly bound oxygen-containing groups
- C07D 265/32: with oxygen atoms directly attached to ring carbon atoms
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

This invention is concerned with mammalian metabolites of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)-phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine which is a tachykinin receptor antagonist that is useful in the prevention and treatment of certain disorders, including emesis and psychiatric disorders such as depression and anxiety.

## Claims

### Claim 1

A compound which is selected from the group consisting of:
and pharmaceutically acceptable salts and individual diasteromers thereof in pure or partially purified form.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of claim 1.

### Claim 3 (depends on 1)

A method for antagonizing the effect of substance P at its receptor site or for the blockade of neurokinin-1 receptors in a mammal which comprises the administration to the mammal of the compound of claim 1 in an amount that is effective for antagonizing the effect of substance P at its receptor site in the mammal.

### Claim 4 (depends on 1)

A method for the treatment of depression in a mammal in need thereof which comprises the administration to the mammmal of an effective amount of the compound of claim 1.

### Claim 5 (depends on 1)

A method for the treatment of anxiety in a mammal in need thereof which comprises the administration to the mammmal of an effective amount of the compound of claim 1.

### Claim 6 (depends on 1)

A method for the treatment or prevention of emesis in a mammal in need thereof which comprises the administration to the mammal of an effective amount of the compound of claim 1.
